BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32540218)

  • 1. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy.
    Weiner AB; Faisal FA; Davicioni E; Karnes RJ; Griend DJV; Lotan TL; Schaeffer EM
    Eur Urol Oncol; 2021 Dec; 4(6):955-962. PubMed ID: 32540218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homeobox B13 G84E Mutation and Prostate Cancer Risk.
    Nyberg T; Govindasami K; Leslie G; Dadaev T; Bancroft E; Ni Raghallaigh H; Brook MN; Hussain N; Keating D; Lee A; McMahon R; Morgan A; Mullen A; Osborne A; Rageevakumar R; ; Kote-Jarai Z; Eeles R; Antoniou AC
    Eur Urol; 2019 May; 75(5):834-845. PubMed ID: 30527799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers.
    Yao J; Chen Y; Nguyen DT; Thompson ZJ; Eroshkin AM; Nerlakanti N; Patel AK; Agarwal N; Teer JK; Dhillon J; Coppola D; Zhang J; Perera R; Kim Y; Mahajan K
    Sci Rep; 2019 Jul; 9(1):9715. PubMed ID: 31273254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness.
    Storebjerg TM; Høyer S; Kirkegaard P; Bro F; ; Ørntoft TF; Borre M; Sørensen KD
    BJU Int; 2016 Oct; 118(4):646-53. PubMed ID: 26779768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
    Johng D; Torga G; Ewing CM; Jin K; Norris JD; McDonnell DP; Isaacs WB
    Prostate; 2019 Mar; 79(4):414-424. PubMed ID: 30560549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
    Patel RA; Sayar E; Coleman I; Roudier MP; Hanratty B; Low JY; Jaiswal N; Ajkunic A; Dumpit R; Ercan C; Salama N; O'Brien VP; Isaacs WB; Epstein JI; De Marzo AM; Trock BJ; Luo J; Brennen WN; Tretiakova M; Vakar-Lopez F; True LD; Goodrich DW; Corey E; Morrissey C; Nelson PS; Hurley PJ; Gulati R; Haffner MC
    J Pathol; 2024 Jan; 262(1):105-120. PubMed ID: 37850574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
    Bhanvadia RR; VanOpstall C; Brechka H; Barashi NS; Gillard M; McAuley EM; Vasquez JM; Paner G; Chan WC; Andrade J; De Marzo AM; Han M; Szmulewitz RZ; Vander Griend DJ
    Clin Cancer Res; 2018 Aug; 24(15):3668-3680. PubMed ID: 29716922
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy.
    Beebe-Dimmer JL; Isaacs WB; Zuhlke KA; Yee C; Walsh PC; Isaacs SD; Johnson AM; Ewing CE; Humphreys EB; Chowdhury WH; Montie JE; Cooney KA
    BJU Int; 2014 May; 113(5):830-5. PubMed ID: 24148311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
    Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
    Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOXB13 contributes to G1/S and G2/M checkpoint controls in prostate.
    Hamid SM; Cicek S; Karamil S; Ozturk MB; Debelec-Butuner B; Erbaykent-Tepedelen B; Varisli L; Gonen-Korkmaz C; Yorukoglu K; Korkmaz KS
    Mol Cell Endocrinol; 2014 Mar; 383(1-2):38-47. PubMed ID: 24325868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
    Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma.
    Timofte AD; Giuşcă SE; Lozneanu L; Manole MB; Prutianu I; Gafton B; Rusu A; Căruntu ID
    Rom J Morphol Embryol; 2021; 62(1):41-52. PubMed ID: 34609407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk.
    Karlsson R; Aly M; Clements M; Zheng L; Adolfsson J; Xu J; Grönberg H; Wiklund F
    Eur Urol; 2014 Jan; 65(1):169-76. PubMed ID: 22841674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.
    Shao YH; Kim S; Moore DF; Shih W; Lin Y; Stein M; Kim IY; Lu-Yao GL
    Eur Urol; 2014 Apr; 65(4):693-700. PubMed ID: 23759328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans.
    VanOpstall C; Perike S; Brechka H; Gillard M; Lamperis S; Zhu B; Brown R; Bhanvadia R; Vander Griend DJ
    Elife; 2020 Jun; 9():. PubMed ID: 32553107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
    Na R; Wei J; Sample CJ; Gielzak M; Choi S; Cooney KA; Rabizadeh D; Walsh PC; Zheng LS; Xu J; Isaacs WB
    Br J Cancer; 2022 Mar; 126(5):791-796. PubMed ID: 34799695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.
    Kim YR; Oh KJ; Park RY; Xuan NT; Kang TW; Kwon DD; Choi C; Kim MS; Nam KI; Ahn KY; Jung C
    Mol Cancer; 2010 May; 9():124. PubMed ID: 20504375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.
    Varinot J; Furudoï A; Drouin S; Phe V; Penna RR; Roupret M; Bitker MO; Cussenot O; Compérat E
    Virchows Arch; 2016 May; 468(5):619-22. PubMed ID: 26931741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers.
    Lotan TL; Torres A; Zhang M; Tosoian JJ; Guedes LB; Fedor H; Hicks J; Ewing CM; Isaacs SD; Johng D; De Marzo AM; Isaacs WB
    Oncotarget; 2017 Apr; 8(14):22772-22782. PubMed ID: 28186998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.